Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma
Importance: Combining immune checkpoint blockade (ICB) with chemotherapy improves outcomes in patients with metastatic gastric and gastroesophageal junction (G/GEJ) adenocarcinoma; however, whether this combination has activity in the perioperative setting remains unknown.
Objective: To evaluate the safety and preliminary activity of perioperative chemotherapy and ICB followed by maintenance ICB in resectable G/GEJ adenocarcinoma.
Design, Setting, and Participants: This investigator-initiated, multicenter, open-label, single-stage, phase 2 nonrandomized controlled trial screened 49 patients and enrolled 36 patients with resectable G/GEJ adenocarcinoma from February 10, 2017, to June 17, 2021, with a median (range) follow-up of 35.2 (17.4-73.0) months. Thirty-four patients were deemed evaluable for efficacy analysis, with 28 (82.4%) undergoing curative resection. This study was performed at 4 referral institutions in the US.
Interventions: Patients received 3 cycles of capecitabine, 625 mg/m2, orally twice daily for 21 days; oxaliplatin, 130 mg/m2, intravenously and pembrolizumab, 200 mg, intravenously with optional epirubicin, 50 mg/m2, every 3 weeks before and after surgery with an additional cycle of pembrolizumab before surgery. Patients received 14 additional doses of maintenance pembrolizumab.
Main Outcomes and Measures: The primary end point was pathologic complete response (pCR) rate. Secondary end points included overall response rate, disease-free survival (DFS), overall survival (OS), and safety.
Results: A total of 34 patients (median [range] age, 65.5 [25-90] years; 23 [67.6%] male) were evaluable for efficacy. Of these patients, 28 (82.4%) underwent curative resection, 7 (20.6%; 95% CI, 10.1%-100%) achieved pCR, and 6 (17.6%) achieved a pathologic near-complete response. Of the 28 patients who underwent resection, 4 (14.3%) experienced disease recurrence. The median DFS and OS were not reached. The 2-year DFS was 67.8% (95% CI, 0.53%-0.87%) and the OS was 80.6% (95% CI, 0.68%-0.96%). Treatment-related grade 3 or higher adverse events for evaluable patients occurred in 20 patients (57.1%), and 12 (34.3%) experienced immune-related grade 3 or higher adverse events.
Conclusion and Relevance: In this trial of unselected patients with resectable G/GEJ adenocarcinoma, capecitabine, oxaliplatin, and pembrolizumab resulted in a pCR rate of 20.6% and was well tolerated. This trial met its primary end point and supports the development of checkpoint inhibition in combination with perioperative chemotherapy in locally advanced G/GEJ adenocarcinoma.
Trial Registration: ClinicalTrials.gov Identifier: NCT02918162.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
JAMA oncology - 9(2023), 12 vom: 01. Dez., Seite 1702-1707 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Manji, Gulam A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
04ZR38536J |
|---|
| Anmerkungen: |
Date Completed 22.12.2023 Date Revised 06.03.2024 published: Print ClinicalTrials.gov: NCT02918162 Citation Status MEDLINE |
|---|
| doi: |
10.1001/jamaoncol.2023.4423 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363485813 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363485813 | ||
| 003 | DE-627 | ||
| 005 | 20240306232459.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jamaoncol.2023.4423 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM363485813 | ||
| 035 | |a (NLM)37856106 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Manji, Gulam A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.12.2023 | ||
| 500 | |a Date Revised 06.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT02918162 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Importance: Combining immune checkpoint blockade (ICB) with chemotherapy improves outcomes in patients with metastatic gastric and gastroesophageal junction (G/GEJ) adenocarcinoma; however, whether this combination has activity in the perioperative setting remains unknown | ||
| 520 | |a Objective: To evaluate the safety and preliminary activity of perioperative chemotherapy and ICB followed by maintenance ICB in resectable G/GEJ adenocarcinoma | ||
| 520 | |a Design, Setting, and Participants: This investigator-initiated, multicenter, open-label, single-stage, phase 2 nonrandomized controlled trial screened 49 patients and enrolled 36 patients with resectable G/GEJ adenocarcinoma from February 10, 2017, to June 17, 2021, with a median (range) follow-up of 35.2 (17.4-73.0) months. Thirty-four patients were deemed evaluable for efficacy analysis, with 28 (82.4%) undergoing curative resection. This study was performed at 4 referral institutions in the US | ||
| 520 | |a Interventions: Patients received 3 cycles of capecitabine, 625 mg/m2, orally twice daily for 21 days; oxaliplatin, 130 mg/m2, intravenously and pembrolizumab, 200 mg, intravenously with optional epirubicin, 50 mg/m2, every 3 weeks before and after surgery with an additional cycle of pembrolizumab before surgery. Patients received 14 additional doses of maintenance pembrolizumab | ||
| 520 | |a Main Outcomes and Measures: The primary end point was pathologic complete response (pCR) rate. Secondary end points included overall response rate, disease-free survival (DFS), overall survival (OS), and safety | ||
| 520 | |a Results: A total of 34 patients (median [range] age, 65.5 [25-90] years; 23 [67.6%] male) were evaluable for efficacy. Of these patients, 28 (82.4%) underwent curative resection, 7 (20.6%; 95% CI, 10.1%-100%) achieved pCR, and 6 (17.6%) achieved a pathologic near-complete response. Of the 28 patients who underwent resection, 4 (14.3%) experienced disease recurrence. The median DFS and OS were not reached. The 2-year DFS was 67.8% (95% CI, 0.53%-0.87%) and the OS was 80.6% (95% CI, 0.68%-0.96%). Treatment-related grade 3 or higher adverse events for evaluable patients occurred in 20 patients (57.1%), and 12 (34.3%) experienced immune-related grade 3 or higher adverse events | ||
| 520 | |a Conclusion and Relevance: In this trial of unselected patients with resectable G/GEJ adenocarcinoma, capecitabine, oxaliplatin, and pembrolizumab resulted in a pCR rate of 20.6% and was well tolerated. This trial met its primary end point and supports the development of checkpoint inhibition in combination with perioperative chemotherapy in locally advanced G/GEJ adenocarcinoma | ||
| 520 | |a Trial Registration: ClinicalTrials.gov Identifier: NCT02918162 | ||
| 650 | 4 | |a Controlled Clinical Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Capecitabine |2 NLM | |
| 650 | 7 | |a 6804DJ8Z9U |2 NLM | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a Oxaliplatin |2 NLM | |
| 650 | 7 | |a 04ZR38536J |2 NLM | |
| 700 | 1 | |a Lee, Shing |e verfasserin |4 aut | |
| 700 | 1 | |a Del Portillo, Armando |e verfasserin |4 aut | |
| 700 | 1 | |a May, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Ana, Sarah Sta |e verfasserin |4 aut | |
| 700 | 1 | |a Alouani, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Sender, Naomi |e verfasserin |4 aut | |
| 700 | 1 | |a Negri, Tiffany |e verfasserin |4 aut | |
| 700 | 1 | |a Gautier, Katarzyna |e verfasserin |4 aut | |
| 700 | 1 | |a Ge, Liner |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Weijia |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Mengyu |e verfasserin |4 aut | |
| 700 | 1 | |a Sethi, Amrita |e verfasserin |4 aut | |
| 700 | 1 | |a Schrope, Beth |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Aik Choon |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Haeseong |e verfasserin |4 aut | |
| 700 | 1 | |a Oberstein, Paul E |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Manish A |e verfasserin |4 aut | |
| 700 | 1 | |a Raufi, Alexander G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JAMA oncology |d 2015 |g 9(2023), 12 vom: 01. Dez., Seite 1702-1707 |w (DE-627)NLM250070588 |x 2374-2445 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2023 |g number:12 |g day:01 |g month:12 |g pages:1702-1707 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1001/jamaoncol.2023.4423 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2023 |e 12 |b 01 |c 12 |h 1702-1707 | ||